Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production

Cancer Research

Volumn 58, Issue 6, 1998, Pages 1208-1216

  Huang, Min ^a   Stolina, Marina ^a   Sharma, Sherven ^a   Mao, Jenny T ^a   Zhu, Li ^a   Miller, Patrice W ^a   Wollman, Jerome ^a   Herschman, Harvey ^a   Dubinett, Steven M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLOOXYGENASE 2; INTERLEUKIN 10; INTERLEUKIN 12; PROSTAGLANDIN E2; RECOMBINANT INTERLEUKIN 1BETA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MACROPHAGE MIGRATION INHIBITION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032521401     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornard, T., Fontana, A., Lienard, D., Cerottini, J-C., and Tschopp, J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 1363-1366, 1996.
2. Gimmi, C. D., Morrison, B. W., Mainprice, B. A., Gribben, J. G., Boussiotis, V. A., Freeman, G. J., Park, S. Y. L., Watanabe, M., Gong, J., Hayes, D. F., Kufe, D. W., and Nadler, L. M. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat. Med., 2: 1367-1370, 1996.
3. Mizoguchi, H., O'Shea, J., Longo, D., Leffler, C., McVicar, D., and Ochoa, A. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (Washington DC), 258: 1795-1798, 1992.
4. Sulitzeanu, D. Immunosuppressive factors in human cancer. Adv. Cancer Res., 60: 247-267, 1993.
5. Dubinett, S. M., and Kradin, R. L. Cytokine immunotherapy of non-small cell lung cancer. Reg. Immunol., 5: 232-242, 1993.
6. Yoshino, I., Yano, T., Murata, M., Ishida, T., Sugimachi, K., Kimura, G., and Nomoto, K. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res., 52: 775-781, 1992.
7. Smith, D. R., Kunkel, S. L., Burdick, M. D., Wilke, C. A., Orringer, M. B., Whyte, R. I., and Strieter, R. M. Production of interleukin-10 by human bronchogenic carcinoma. Am. J. Pathol., 145: 18-25, 1994.
8. 2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J. Immunol., 157: 5512-5520, 1996.
9. Alleva, D. G., Burger, C. J., and Elgert, K. D. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production: role of tumor-derived IL-10, TGF-β and prostaglandin E2. J. Immunol., 153: 1674-1686, 1994.
10. Herschman, H. Review. Prostaglandin synthase 2. Biochim. Biophys. Acta, 1299: 125-140, 1996.
11. 2 synthesis by human lung fibroblasts. Am. J. Respir. Cell Mol. Biol., 12: 358-365, 1995.
12. Herschman, H. R., Kujubu, D. A., Fletcher, B. S., Ma, Q., Varnum, B. C., Gilbert, R. S., and Reddy, S. T. The tis genes, primary response genes induced by growth factors and tumor promoters in 3T3 cells. Prog. Nucleic Acids Res. Mol. Biol., 47: 113-148, 1994.
13. Hla, T., and Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA, 89: 7384-7388, 1992.
14. O'Banion, M. K., Winn, V. D., and Young, D. A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA, 89: 4888-4892, 1992.
15. 2 in human prostatic carcinoma cells. Br. J. Cancer, 75: 1111-1118, 1997.
16. D'Andrea, A., Aste-Amezaga, M., Valiante, N., Ma, X., Kubin, M., and Trinchieri, G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med., 178: 1041-1048, 1993.
17. Wu, C-Y., Demeure, C., Kiniwa, M., Gately, M., and Delespesse, G. IL-12 induces the production of IFN-γ by neonatal human CD4 T cells. J. Immunol., 151: 1938-1949, 1993.
18. Kim, J., Modlin, R. L., Moy, R. L., Dubinett, S. M., McHugh, T., Nickoloff, B. J., and Uyemura, K. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J. Immunol., 155: 2240-2247, 1995.
19. Qin, Z., Noffz, G., Mohaupt, M., and Blankenstein, T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol., 159: 770-776, 1997.
20. Bianchi, R., Grohmann, U., Belladonna, M., Silla, S., Fallarino, F., Ayroldi, E., Fioretti, M., and Puccetti, P. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol., 157: 1589-1597, 1996.
21. Colombo, M., Vagliani, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C., and Stoppacciaro, A. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res., 56: 2531-2534, 1996.
22. Handel-Fernandez, M. E., Ching, X., Herbert, L. M., and Lopez, D. M. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J. Immunol., 158: 280-286, 1997.
23. Stolina, M., Sharma, S., Huang, M., Lin, Y., Zhu, L., Chen, K., Lim, K., Miller, P., and Dubinett, S. Tumor cyclooxygenase-dependent modulation of lymphocyte IL-10 production in murine lung cancer. Proc. Am. Assoc. Cancer Res., 38: 121, 1997.
24. Tsujii, M., Kawano, S., and DuBois, R. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA, 94: 3336-3340, 1997.
25. Eberhart, C., Coffey, R., Radhika, A., Giardiello, F., Ferrenbach, S., and DuBois, R. Up-regulation of cyclooxygenase gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.
26. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., and Hla, T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55: 3785-3789, 1995.
27. Liu, X-H., and Rose, D. P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res., 56: 5125-5127, 1996.
28. Huang, M., Wang, J., Lee, P., Sharma, S., Mao, J. T., Meissner, H., Uyemura, K., Modlin, R., Wollman, J., and Dubinett, S. M. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res., 55: 3847-3853, 1995.
29. Futaki, N., Takahashi, S., Yokoyama, M., Arai, I., Higuchi, S., and Otomo, S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins, 47: 55-59, 1994.
30. 2. J. Immunol., 155: 4437-4444, 1995.
31. Key, G., Peterson, J., Becker, M., Duchrow, M., Schluter, C., Askaa, J., and Gerdes, J. New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections. J. Clin. Pathol., 46: 1080-1084, 1993.
32. Diaz, A., Reginato, A., and Jimenez, S. Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor β1, interleukin 1β, and tumor necrosis factor α. J. Biol. Chem., 267: 10816-10822, 1992.
33. Otto, J. C., DeWitt, D. L., and Smith, W. L. N-Glycosylation of prostaglandin endoperoxidase synthases-1 and -2 and their orientations in the endoplasmic reticulum. J. Biol. Chem., 268: 18234-18242, 1993.
34. Sirois, J., and Richards, J. S. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxidase synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J. Biol. Chem., 267: 6382-6388, 1992.
35. Smith, W. L., and DeWitt, D. L. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin. Nephrol., 15: 179-194, 1995.
36. 2 production in mast cells. J. Immunol., 155: 818-825, 1995.
37. Van der Pouw Kraan, T., Boeije, L., Smeenk, R., Wijdenes, J., and Aarden, L. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med., 181: 775-779, 1995.
38. Balch, C. M., Doghert, P. A., Cloud, G. A., and Tilden, A. B. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery, 95: 71-77, 1984.
39. Lala, P. K., Elkashab, M., Kerbel, R. S., and Parhar, R. S. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ. Int. J. Immunol., 2: 1149-1158, 1990.
40. Mertens, W. C., Bramwell, V. H., Banerjee, D., Gwadry-Sridhar, F., and Lala, P. K. Sustained indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced malignant melanoma: a phase II study. Clin. Oncol., 5: 107-113, 1993.
41. Chiabrando, C., Broggini, M., Castagnoli, M. N., Donelli, M. G., Noseda, A., Visintainer, M., Garattini, S., and Fanelli, R. Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth. Cancer Res., 45: 3605-3608, 1985.
42. Maca, R. D. Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude, and beige mice. J. Biol. Response Modif., 7: 568-580, 1988.
43. Young, M. R., and Knies, S. Prostaglandin E production by Lewis lung carcinoma: mechanism for tumor establishment in vivo. J. Natl. Cancer Inst., 72: 919-922, 1984.
44. Funahashi, A., Harland, R. W., and LeFever, A. Association of increased prostaglandin E2 content in bronchoalveolar lavage fluid and intrathoracic malignancy. Chest, 106: 166-172, 1994.
45. LeFever, A., and Funahashi, A. Elevated prostaglandin E2 levels in bronchoalveolar lavage fluid of patients with bronchogenic carcinoma. Chest, 98: 1397-1402, 1990.
46. Eisenthal, A. Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular toxicity mediated by interleukin-2. Cancer Immunol. Immunother., 31: 342-348, 1990.
47. 2. J. Exp. Med., 180: 2365-2370, 1994.
48. Kujubu, D. A., and Herschman, H. R. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase cyclooxygenase gene. J. Biol. Chem., 267: 7991-7994, 1992.
49. Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., and Herschman, H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem., 266: 12866-12872, 1991.
50. Lee, S. H., Soyoola, E., Chanmugam, P., Hart, S., Sun, W., Zhong, H., Liou, S., Simmons, D., and Hwang, D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem., 267: 25934-25938, 1992.
51. Kujubu, D. A., Reddy, S. T., Fletcher, B. S., and Herschman, H. R. Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated swiss 3T3 cells. J. Biol. Chem., 268: 5425-5430, 1993.
52. Ihara, H., Yokoyama, C., Miyata, A., Kosaka, T., Nusing, R., Ullrich, V., and Tanebe, T. Induction of thromboxane synthase and prostaglandin endoperoxide synthase mRNAs in human erythroleukemia cells by phorbol ester. FEBS Lett., 306: 161-164, 1992.
53. Coffey, R. J., Hawkey, C. J., Damstrup, L., Graves-Deal, R., Daniel, V. C., Dempsey, P. J., Chinery, R., Kirkland, S. C., DuBois, R. N., Jetton, T. L., and Morrow, J. D. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Natl. Acad. Sci. USA, 94: 657-662, 1997.
54. Lin, A. H., Bienkowski, M. J., and Gorman, R. R. Regulation of prostaglandin H synthase mRNA levels and prostaglandin biosynthesis by platelet-derived growth factor. J. Biol. Chem., 264: 17379-17383, 1989.
55. Gilbert, R. S., and Herschman, H. R. Transforming growth factor β differentially modulates the inducible nitric oxide synthase gene in distinct cell types. Biochem. Biophys. Res. Commun., 195: 380-384, 1993.
56. Gilbert, R. S., Reddy, S. T., Targan, S., and Herschman, H. R. TGF-β1 augments expression of the TIS10/prostaglandin synthase-2 gene in intestinal epithelial cells. Cell. Mol. Biol. Res., 40: 653-660, 1994.
57. 1 augments mitogen-induced prostaglandin synthesis and expression of the TIS10/prostaglandin synthase 2 gene both in Swiss 3T3 cells and in murine embryo fibroblasts. J. Cell. Physiol., 159: 67-75, 1994.
58. Aksamit, T. R., and Hunninghake, G. W. Interleukin-1. In: C. Lenfant and J. Kelley (ed.), Cytokines of the Lung, pp. 185-228. New York: Marcel Dekker, Inc., 1993.
59. Warnock, L. J., and Hunninghake, G. W. Multiple second messenger pathways regulate IL-1 β-induced expression of PGHS-2 mRNA in normal human skin fibroblasts. J. Cell. Physiol., 163: 172-178, 1995.
60. Mitra, R. S., Judge, T. A., Nestle, F. O., Turka, L. A., and Nickoloff, B. J. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. J. Immunol., 154: 2668-2677, 1995.
61. de Waal-Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., Te Velde, A., Fidgor, C., Johnson, K., Kastelein, R., Yssel, H., and De Vries, J. E. Interleukin-10 (IL10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class-II major histocompatibility complex expression. J. Exp. Med., 174: 915-924, 1991.
62. Taga, K., and Tosato, G. IL-10 inhibits human T cell proliferation and IL-2 production. J. Immunol., 148: 1143-1148, 1992.
63. Florentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W., and O'Garra, A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol., 146: 3444-3451, 1991.
64. Mosmann, T., and Moore, K. W. The role of IL-10 in cross-regulation of TH1 and TH2 responses. Immunol. Today, 12: A49-A53, 1991.
65. Matsuda, M., Salazar, F., Petersson, M., Masucci, G., Hansson, J., Pisa, P., Zhang, Q., Masucci, M. G., and Kiessling, R. Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med., 180: 2371-2376, 1994.
66. Salazar-Onfray, F., Petersson, M., Franksson, L., Matsuda, M., Blankenstein, T., Kärre, K., and Kiessling, R. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J. Immunol., 154: 6291-6298, 1995.
67. Hagenbaugh, A., Sharma, S., Dubinett, S., Wei, S. H-Y., Aranda, R., Cheroutre, H., Fowell, D., Binder, S., Tsao, B., Locksley, R., Moore, K., and Kronenberg, M. Altered immune responses in IL-10 transgenic mice. J. Exp. Med., 185: 2101-2110, 1997.
68. Rohrer, J. W., and Coggin, J. H., Jr. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J. Immunol., 155: 5719-5727, 1995.
69. Fallarino, F., Uyttenhove, C., Boon, T., and Gawjewski, T. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol., 156: 1095-1100, 1996.
70. Szabo, S. J., Jacobson, N. G., Digne, A. S., Gubler, U., and Murphy, K. M. Development commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity, 2: 665-675, 1995.
71. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
72. Coughlin, C. M., Wysocka, M., Kurzawa, H. L., Lee, W. M. F., Trinchieri, G., and Eck, S. L. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res., 55: 4980-4987, 1995.
73. Tahara, H., Zeh, H. J., III, Storkus, W. J., Pappa, I., Watkins, S. C., Gubler, U., Wolf, S. F., Robbins, P. D., and Lotze, M. T. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res., 54: 182-189, 1994.
74. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol., 154: 6466-6474, 1995.
75. + T cells. J. Immunol., 156: 1722-1727, 1996.
76. Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., and Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333: 609-614, 1995.
77. Marcus, A. J. Aspirin as prophylaxis against colorectal cancer. N. Engl. J. Med., 333: 656-657, 1995.
78. Kargman, S. L., O'Neill, G. P., Vickers, P. J., Evans, J. F., Mancini, J. A., and Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55: 2556-2559, 1995.
79. Reddy, B., Rao, C., and Seibert, K. Evaluation of cyclooxygenase 2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res., 56: 4566-4569, 1996.
80. Tsujii, M., and DuBois, R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell, 83: 493-501, 1995.
81. Boolbol, S., Dannenber, A., Chadburn, A., Martucci, C., Guo, X., Ramonetti, J., Abreu-Goris, M., Newmark, H., Lipkin, M., DeCosse, J., and Bertagnolli, M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56: 2556-2560, 1996.
82. D716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
83. Tang, D. C., and Carbone, D. P. Potential application of gene therapy to lung cancer. Semin. Oncol., 20: 368-373, 1993.
84. Johnson, B. E., and Johnson, D. H. Lung Cancer. In: A. M. Mauer and J. E. Ultmann (eds.), Current Clinical Oncology, pp. xiii-xiv. New York: Wiley-Liss, Inc., 1995.